Barclays lowered the firm’s price target on Elanco (ELAN) to $19 from $22 and keeps an Overweight rating on the shares as part of a Q3 preview for the specialty pharmaceuticals.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAN:
- Elanco’s Zenrelia™ Study Shows Promising Results in Dogs
- Investors in Elanco Animal Health Incorporated Should Contact Levi & Korsinsky LLP Before December 06, 2024 to Discuss Your Rights – ELAN
- Elanco receives FDA approval of Credelio Quattro
- Elanco price target raised to $22 from $21 at Barclays
- Elanco announces FDA approval of Zenrelia